Variant von Willebrand's disease and pregnancy.
The clinical course and coagulation profile of a pregnant patient with variant von Willebrand's disease were followed from the second trimester through puerperium. The clinical course was characterized by a normal delivery and absence of abnormal bleeding or need for replacement therapy. The coagulation profile demonstrated an increase in factor VIII procoagulant activity, factor-VIII-related antigen, and platelet aggregation activity in response to ristocetin prior to delivery. Postpartum, these factors decreased to prepregnancy values with distinctly different patterns. Factor VIII procoagulant activity continued to rise for 5 days after delivery and then decreased with a half-life of approximately 6 days. Factor-VIII-related antigen began to decrease just prior to delivery, displaying a half-life or approximately 6 days. Ristocetin cofactor activity, however, dropped immediately postpartum and displayed a half-life of approximately 6 hr. The ristocetin cofactor activity was associated with factor-VIII-related antigen, which displayed a significantly smaller molecular weight than does normal factor-VIII-related antigen. Larger aggregates of factor-VIII-related antigen. Larger aggregates of factor-VIII-related antigen did not appear during the pregnancy, and ristocetin cofactor activity could not be demonstrated in fragments of less than 0,8 x 10(6).
D000328:Adult; D000941:Antigens; D001760:Bleeding Time; D004958:Estradiol / Q000097:blood; D005169:Factor VIII / Q000276:immunology; D005260:Female; D014644:Genetic Variation; D006801:Humans; D010314:Partial Thromboplastin Time; D010973:Platelet Adhesiveness; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000235:genetics*; D011517:Prothrombin Time; D014842:von Willebrand Diseases / Q000235:genetics*; D014841:von Willebrand Factor / Q000378:metabolism
D000941:Antigens; D014841:von Willebrand Factor; D004958:Estradiol; D005169:Factor VIII